William Blair upgraded shares of Sientra, Inc. (NASDAQ:SIEN) from a market perform rating to an outperform rating in a report issued on Wednesday morning, Marketbeat.com reports.
Other research analysts have also recently issued research reports about the company. Lake Street Capital restated a buy rating and issued a $15.00 price target (up previously from $11.00) on shares of Sientra in a research report on Tuesday, August 8th. Canaccord Genuity started coverage on Sientra in a research report on Monday, August 28th. They issued a buy rating and a $14.00 price target on the stock. ValuEngine upgraded Sientra from a sell rating to a hold rating in a research report on Thursday, June 22nd. Zacks Investment Research upgraded Sientra from a sell rating to a hold rating in a research report on Wednesday, July 12th. Finally, Stephens started coverage on Sientra in a research report on Tuesday, July 11th. They issued an overweight rating and a $12.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $13.67.
Shares of Sientra (SIEN) traded up 4.89% during midday trading on Wednesday, hitting $15.44. 270,389 shares of the stock traded hands. Sientra has a 1-year low of $6.92 and a 1-year high of $15.46. The company’s market capitalization is $298.08 million. The stock has a 50 day moving average of $11.34 and a 200 day moving average of $9.43.
Sientra (NASDAQ:SIEN) last issued its quarterly earnings results on Wednesday, August 9th. The medical instruments supplier reported ($0.55) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.59) by $0.04. Sientra had a negative return on equity of 52.30% and a negative net margin of 173.83%. The company had revenue of $8.20 million for the quarter, compared to analysts’ expectations of $6.97 million. The company’s revenue was up 32.3% compared to the same quarter last year. Equities research analysts predict that Sientra will post ($2.94) earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System bought a new position in shares of Sientra in the second quarter worth $246,000. State Street Corp bought a new position in shares of Sientra in the second quarter worth $1,449,000. Cloverdale Capital Management LLC increased its position in shares of Sientra by 28.9% in the second quarter. Cloverdale Capital Management LLC now owns 492,237 shares of the medical instruments supplier’s stock worth $4,785,000 after purchasing an additional 110,495 shares during the period. Bamco Inc. NY increased its position in shares of Sientra by 109.3% in the second quarter. Bamco Inc. NY now owns 471,500 shares of the medical instruments supplier’s stock worth $4,583,000 after purchasing an additional 246,183 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in shares of Sientra by 23.4% in the second quarter. Dimensional Fund Advisors LP now owns 18,660 shares of the medical instruments supplier’s stock worth $181,000 after purchasing an additional 3,534 shares during the period. Institutional investors own 77.61% of the company’s stock.
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
Receive News & Ratings for Sientra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.